A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)

Journal of Infectious Diseases

Volumn 173, Issue 6, 1996, Pages 1336-1346

  Valentine, Fred T ^a   Kundu, Smriti ^e   Haslett, Patrick A J ^e   Katzenstein, David ^e   Beckett, Laurel ^b   Spino, Cathie ^e   Borucki, Michael ^c   Vasquez, Margarita ^e   Smith, Gale ^e   Korvick, Joyce ^d   Kagan, Jonathan ^e   Merigan, Thomas C ^e  

^a NEW YORK UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ERYTHEMA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VACCINATION;

EID: 9444236148     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.6.1336     Document Type: Article

References (15)

1. Clark SJ, Saag MS, Decker WD. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
2. Darr ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency type 2 infection. N Engl J Med 1991;324:961-4.
3. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
4. Embretson J, Zupanic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
5. Ho DD, Moudgil T, Alain M. Quantitation of human immunodeficiency virus type 2 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
6. Coombs RW, Collier AC, Allain JP. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
7. Pantaleo G, Grazios C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35.
8. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
9. Muñoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immune deficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993;137:423-38.
10. Robert-Gruroff M, Brown M, Gallo RC. HTLV-IH-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985;316:72-4.
11. Bolognesi DP. HIV antibodies and vaccine design. AIDS 1989;3(suppl 1):S111-8.
12. Nixon DF, Broliden K, Ogg G, Broliden P. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992;76:515-34.
13. Walker BD, Chakrabarti S, Moss BD, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-8.
14. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallway J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988;336:484-7.
15. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-23.